SRNE - Sorrento issued regulatory nod for rapid COVID-19 test in Brazil

Sorrento Therapeutics (SRNE +2.3%) announced that the national agency for approval of food, cosmetics, and medical devices (ANVISA) in Brazil has authorized COVISTIX, a rapid diagnostic test for the detection of SARS-CoV-2 antigen. With the ANVISA approval for the test, COVISTIX will now be allowed for point of care use in symptomatic patients in Brazil. The regulatory nod will lead to the immediate commercial launch of COVISTIX in the country as well as several Latin American nations with close ties to its market, Sorrento (NASDAQ:SRNE) said in a statement. “We have been building our manufacturing capacity in anticipation of EUA clearances in multiple countries in need of highly sensitive, and simple COVID-19 rapid antigen testing,” remarked Henry Ji, CEO of the company. Last month, Sorrento (SRNE) was issued the CE Mark certification for the rapid antigen test.

For further details see:

Sorrento issued regulatory nod for rapid COVID-19 test in Brazil